ecteinascidin 743 has been researched along with Carcinoma in 5 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 2 (40.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Adam, JP; Boumedien, F; Letarte, N; Provencher, D | 1 |
Amadio, G; Carpano, S; Ferrandina, G; Loizzi, V; Lorusso, D; Marinaccio, M; Naglieri, E; Salutari, V; Scambia, G; Tonini, G; Vincenzi, B | 1 |
González Martín, A | 1 |
Comisso, M; Koeppel, F; Larsen, AK; Poindessous, V; Raymond, E; Waters, SJ | 1 |
De Pooter, CM; Faircloth, GT; Korst, AE; Lambrechts, HA; Lardon, F; Pattyn, GG; Simoens, C; Vermorken, JB | 1 |
1 review(s) available for ecteinascidin 743 and Carcinoma
Article | Year |
---|---|
Safety profile of trabectedin in combination with liposomal pegylated doxorrubicin in relapsed ovarian carcinoma: considerations for optimal management.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dioxoles; Doxorubicin; Female; Humans; Liposomes; Ovarian Neoplasms; Patient Compliance; Quality of Life; Recurrence; Tetrahydroisoquinolines; Trabectedin | 2011 |
4 other study(ies) available for ecteinascidin 743 and Carcinoma
Article | Year |
---|---|
Single agent trabectedin in heavily pretreated patients with recurrent ovarian cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Carcinoma; Dioxoles; Disease-Free Survival; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Ovarian Neoplasms; Retrospective Studies; Tetrahydroisoquinolines; Trabectedin | 2017 |
Trabectedin as single agent in the salvage treatment of heavily treated ovarian cancer patients: a retrospective, multicenter study.
Topics: Adult; Aged; Alanine Transaminase; Antineoplastic Agents, Alkylating; Aspartate Aminotransferases; Asthenia; Carcinoma; Dioxoles; Disease-Free Survival; Drug Resistance, Neoplasm; Female; Humans; Middle Aged; Neutropenia; Ovarian Neoplasms; Platinum Compounds; Retrospective Studies; Salvage Therapy; Tetrahydroisoquinolines; Trabectedin | 2013 |
Marked activity of irofulven toward human carcinoma cells: comparison with cisplatin and ecteinascidin.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Alkylating; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Carcinoma; Cell Line, Tumor; Cisplatin; Culture Media; Dioxoles; Drug Resistance, Neoplasm; Epithelial Cells; Glutamate-Cysteine Ligase; Glutathione Transferase; Humans; Isoquinolines; Models, Chemical; Plant Extracts; Polycyclic Sesquiterpenes; rho GTP-Binding Proteins; Sesquiterpenes; Tetrahydroisoquinolines; Time Factors; Trabectedin; Tumor Suppressor Protein p53 | 2003 |
In vitro interaction between ecteinascidin 743 (ET-743) and radiation, in relation to its cell cycle effects.
Topics: Antineoplastic Agents, Alkylating; Carcinoma; Cell Cycle; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; Dioxoles; Humans; Isoquinolines; Lung Neoplasms; Radiation-Sensitizing Agents; Tetrahydroisoquinolines; Tongue Neoplasms; Trabectedin; Urinary Bladder Neoplasms | 2003 |